Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Accumulated Expenses: 2013-2024

Historic Accumulated Expenses for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Dec 2024 value amounting to $126.5 million.

  • Amphastar Pharmaceuticals' Accumulated Expenses rose 26.12% to $150.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $150.3 million, marking a year-over-year increase of 26.12%. This contributed to the annual value of $126.5 million for FY2024, which is 86.29% up from last year.
  • Amphastar Pharmaceuticals' Accumulated Expenses amounted to $126.5 million in FY2024, which was up 86.29% from $67.9 million recorded in FY2023.
  • In the past 5 years, Amphastar Pharmaceuticals' Accumulated Expenses ranged from a high of $126.5 million in FY2024 and a low of $63.7 million during FY2022.
  • For the 3-year period, Amphastar Pharmaceuticals' Accumulated Expenses averaged around $86.1 million, with its median value being $67.9 million (2023).
  • As far as peak fluctuations go, Amphastar Pharmaceuticals' Accumulated Expenses fell by 5.36% in 2021, and later surged by 86.29% in 2024.
  • Amphastar Pharmaceuticals' Accumulated Expenses (Yearly) stood at $71.1 million in 2020, then dropped by 5.36% to $67.3 million in 2021, then decreased by 5.33% to $63.7 million in 2022, then rose by 6.57% to $67.9 million in 2023, then soared by 86.29% to $126.5 million in 2024.